In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Products Liability Litigation

93 F. App'x 338
CourtCourt of Appeals for the Third Circuit
DecidedFebruary 23, 2004
Docket02-4581
StatusUnpublished
Cited by3 cases

This text of 93 F. App'x 338 (In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Products Liability Litigation) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenfluramine) Products Liability Litigation, 93 F. App'x 338 (3d Cir. 2004).

Opinion

OPINION

CHERTOFF, Circuit Judge.

This appeal is taken from the District Court’s Pretrial Order (PTO) No. 2677 by two law firms on behalf of class members who had previously settled their mass tort claims in the MDL 1203 Diet Drug litigation. The PTO in question extended certain deadlines established under the settlement. Because we conclude that the District Court’s extension of the deadlines was a permissible exercise of its discretion, we will affirm.

I.

We have previously set forth the basic facts in the Diet Drug litigation. See In re Diet Drugs, 282 F.3d 220 (3d Cir.2002). Because this opinion is written only for the parties, we recite only the facts relevant to our decision.

Before 1997, Wyeth, then named American Home Products, 1 sold two prescription drugs for the treatment of obesity, Pondimin and Redux. In September 1997, the United States Food and Drug Administration (FDA) issued a press release stating that a “higher than expected percentage of’ patients taking the drugs “had abnormal echocardiograms, even though they had no symptoms.” 2 Supplemental App. at *340 779. In response to that press release, Wyeth voluntarily withdrew the products from the market. Prior to Wyeth having done so, however, some 5.8 million individuals had used one or the other of the two drugs. Subsequent studies suggest that the drugs may be linked to serious cardiopulmonary side effects — primarily, heart valve regurgitation (the reverse flow of blood through a closed valve of the heart). It is those side effects that are the subject of the Diet Drug litigation at hand.

The federal Diet Drug actions were consolidated for pretrial purposes in the Eastern District of Pennsylvania pursuant to MDL 1203 and, in 1999, Wyeth entered into a Nationwide Class Action Settlement Agreement (the “Settlement Agreement”), executed and approved in that court. Notice to the class explained the nature of the injuries claimed by the plaintiffs and that diagnosis of those injuries (and therefore potential qualification for participation in the Settlement Agreement) was possible through an echocardiogram. The Settlement Agreement was approved by the District Court in August 2000, and it became final on January 3, 2002 (after the exhaustion of all appeals). The Settlement Agreement established, inter alia, a trust (the “Settlement Trust”) to administer Wyeth’s obligations under the Settlement Agreement.

As a threshold for qualifying for certain awards under the Settlement Agreement, class members needed to submit echocardiograms that reported a finding of at least mild mitral valvular regurgitation. Class members had the option of using privately obtained echocardiograms or, if they met certain requirements, obtaining free echocardiogram screening through a program established by the Settlement Agreement (the “Screening Program”). In order to avail themselves of the free screening, however, class members needed to register with the Settlement Trust by August 1, 2002. Under the original settlement, class members had until one year after the finalization of the Settlement Agreement - that is, until January 3, 2003 — to obtain ■ their echocardiographie showing of injury by whatever means they chose.

At some point in 2002, it became clear that, as a practical matter, the Settlement Trust would not be able to administer echocardiograms to all of the class members who had registered for free screening under the Screening Program. This was due to the unexpectedly large influx of requests to take part in the Screening Program. In response, Wyeth and Class Counsel executed a proposed Fifth Amendment to the Settlement Agreement on September 23, 2002. 3 Wyeth and class counsel jointly moved the District Court to approve the amendment and served counsel for all represented plaintiffs (who had not waived service) with notice of the proposed amendment. In addition, the joint motion and the terms of the proposed amendment were posted on the settlement and official MDL 1203 websites.

The original Settlement Agreement read:

49. “Screening Period” refers to the 12-month period (or such longer period that shall be permitted by the Court for good cause shown, but in any case not to exceed 18 months) during which benefits shall be available under the Screening Program.

*341 J.A. 604. The revised language proposed in the Fifth Amendment provides instead:

49. “Screening Period” refers to the 12-month period beginning on the Final Judicial Approval Date during which benefits shall be available in the Screening Program. Class Members who have timely registered for benefits by Date 1 and who are otherwise eligible for Screening Program benefits may receive the Echocardiogram and associated interpretive physician visit benefits after the end of this Screening Period, provided that: (i) all such Echocardiograms must be conducted no later than July 3, 2003, unless the Court, upon a showing of good cause and due diligence by or on behalf of a Class Member or group of Class members, allows the Class Member or group of Class Members to receive an Echocardiogram and associated interpretive physician visit after such date; and (ii) any Class Member who receives an Echocardiogram provided by the [Settlement] Trust after the end of the Screening Period shall be considered to have been diagnosed during the Screening Period for all purposes under this Settlement Agreement, and shall have a period of 120 days after the date of the Echocardiogram to exercise, if otherwise eligible, a right of Intermediate Opt-Out under Section IV.D.S.b.

J.A. 1226. The amended language effectively extended the period of time during which proof of injury could be submitted by class members whose echoeardiographic evaluation was delayed by the influx of Screening Program participants (the “delayed class members”). The language left intact the filing deadlines for all other class members (the “non-delayed class members”) — that is, class members who had already received their echocardiographic evaluation through the Screening Program and class members not participating in the Screening Program (i.e., class members who had privately sought echo-cardiograms).

On November 7, 2002, appellants filed a cross-motion, on behalf of their non-delayed class member clients, in which they agreed that the District Court should approve the extension of the screening period under the proposed amendment. But they asked that the District Court, for good cause, extend the Screening Period through July 3, 2003 for all class members, including non-delayed class members. On October 9, 2002 and November 21, 2002, the District Court held hearings to consider the propriety of approving the proposed Fifth Amendment and appellants’ cross-motion. On December 11, 2002, the District Court issued PTO 2677, approving the Fifth Amendment, and a memorandum supporting its decision. 4 This timely appeal followed.

II.

A.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
93 F. App'x 338, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-diet-drugs-phenterminefenfluraminedexfenfluramine-products-ca3-2004.